Brian Lian, Viking Therapeutics CEO

Meta­bol­ic dis­ease out­fit ac­cus­es Chi­nese biotech of steal­ing trade se­crets to ad­vance com­pet­ing drug

NASH is a big in­di­ca­tion with plen­ty of ben­e­fits to the first com­pa­ny that can suc­cess­ful­ly get a work­ing drug on the mar­ket. And ac­cord­ing to one US biotech, a Chi­nese com­pa­ny stole trade se­crets in or­der to get a head start.

Viking Ther­a­peu­tics is su­ing Chi­nese biotech As­cle­tis Phar­ma in Cal­i­for­nia dis­trict court, claim­ing that As­cle­tis es­sen­tial­ly duped the biotech in­to di­vulging its trade se­crets to the com­pa­ny and gave As­cle­tis the op­por­tu­ni­ty to re­lease its own drug prod­uct to di­rect­ly com­pete with Viking.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.